Consequently, GBA1 supplementation is thought as a disease-modifying therapeutic approach to restore lysosomal homeostasis and reduce α-synuclein neuropathology for the treatment of PD and other α-synuclein-associated neurodegenerative diseases, such as multiple system atrophy, dementia with Lewy bodies, and Alzheimer’s disease [2,34]. The gene discussed is SNCA; the disease is early-onset autosomal dominant Alzheimer disease.